Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from AgomAb Therapeutics NV ADR ( (AGMB) ).
Agomab Therapeutics, a Belgian clinical-stage biopharma focused on fibro-inflammation, is advancing its lead ALK5 inhibitors ontunisertib for fibrostenosing Crohn’s disease and AGMB-447 for idiopathic pulmonary fibrosis through mid-stage development. The company strengthened its balance sheet with €116.5 million in cash and short-term investments at year-end 2025 and added about $208 million of IPO proceeds in February 2026, extending its cash runway into the first half of 2029 despite higher R&D spending and a €62.5 million net loss in 2025.
On April 23, 2026, Agomab reported its full-year 2025 financial results, confirmed its 2026 operational outlook, and detailed plans to start a Phase 2b FSCD trial for ontunisertib and a Phase 2 IPF study for AGMB-447 in the second half of 2026, supported by positive feedback from U.S. and U.K. regulators. The company also highlighted upcoming 2026 data catalysts, including long-term extension results from the STENOVA study in FSCD and Phase 1b IPF cohort data for AGMB-447, while convening an Annual General Meeting for May 26, 2026, to update shareholders on progress and governance matters.
The most recent analyst rating on (AGMB) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on AgomAb Therapeutics NV ADR stock, see the AGMB Stock Forecast page.
More about AgomAb Therapeutics NV ADR
Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on fibro-inflammation, developing small-molecule ALK5 inhibitors for fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. Headquartered in Antwerp and listed on Nasdaq as AGMB, the company targets severe fibrotic and inflammatory conditions with significant unmet medical need.
Average Trading Volume: 225,373
Current Market Cap: $521.5M
For a thorough assessment of AGMB stock, go to TipRanks’ Stock Analysis page.